Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Alliance Fiber Optic Products Inc. (NASDAQ: AFOP) shares surged 12.12 percent to close at $17.30 a share Thursday. The stock traded between $15.36 and $17.45 on volume 1.43 million shares traded. The company is scheduled to release Fourth Quarter and Fiscal Year 2013 results after market close on February 3rd. Shares of Alliance Fiber Optic Products have gained approximately 180.0 percent in the past year.
Get more information on Alliance Fiber Optic Products free access to the in-depth equity report at:
Alimera Sciences Inc. (NASDAQ: ALIM) shares spiked 19.04 percent to close at $7.19 a share Thursday. The stock traded between $6.00 and $7.37 on volume 1.10 million shares traded. The company recently announced that it has shipped its first orders of ILUVIEN to several United Kingdom National Health Service facilities. Shares of Alimera Sciences have gained approximately 310.0 percent in the past year.
Get more information on Alimera Sciences and free access to the in-depth equity report at:
Amarin Corporation plc (NASDAQ: AMRN) shares declined 5.83 percent to close at $2.26 a share Thursday. The stock traded between $2.16 and $2.35 on volume 10.54 million shares traded. The company announced that the FDA has delays its decision to rescind the ANCHOR clinical trial Special Protocol Assessment (SPA) agreement. Shares of Amarin have fallen approximately 70.0 percent in the past year.
Get more information on Amarin and free access to the in-depth equity report at:
Venaxis Inc. (NASDAQ: APPY) shares jumped 11.60percent to close at $2.79 a share Thursday. The stock traded between $2.51 and $2.85 on volume of 1.87 million shares traded. The company recently presented at the Biotech Showcase 2014 conference in San Francisco, CA. Shares of Venaxis have gained approximately 25.0 percent in the past year.
Get more information on Venaxis and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities